Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma (CLARION)
A Randomized, Open-label Phase 3 Study of Carfilzomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
Sponsor: Amgen
Listed as NCT01818752, this PHASE3 trial focuses on Multiple Myeloma and remains completed. Sponsored by Amgen, it has been updated 11 times since 2013, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Sep 2019 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 6 earlier versions
-
Nov 2018 — Sep 2019 [monthly]
Completed PHASE3
-
Jun 2018 — Nov 2018 [monthly]
Completed PHASE3
-
Sep 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jun 2017 — Sep 2017 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2017 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Jul 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Amgen
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Adelaide, Australia , Amsterdam, Netherlands , Ancona, Italy , Ankara, Turkey (Türkiye) , Antwerp, Belgium , Arkhangelsk, Russia , Arlon, Belgium , Athens, Greece , Auckland, New Zealand , Badalona, Spain and 168 more locations